Zymeworks Inc. — Form 8-K Summary
Business context and reporting period
This Current Report on Form 8-K reports a material definitive agreement entered into on April 25, 2023, involving Zymeworks’ zanidatamab development program. The filing is a transaction update rather than a quarterly or annual financial report and does not provide current-period financial statements or operating results.
Transaction and key financial implications
- Zymeworks subsidiaries agreed to transfer the zanidatamab program to Jazz Pharmaceuticals and its affiliates through a stock and asset purchase arrangement.
- Jazz will acquire 100% of the outstanding stock of Zymeworks Zanidatamab Inc., acquire specified program-related assets and contracts, engage certain employees and contractors, and assume specified post-closing liabilities.
- No Zymeworks common stock will be sold to or acquired by Jazz.
- The parties expect to enter into an amended collaboration agreement at closing. The original collaboration agreement’s initial financial terms will remain unchanged.
- Under the amended agreement, Jazz will directly bear program costs, including ongoing costs related to transferred service providers, rather than reimbursing Zymeworks for those costs.
- Jazz will assume sole responsibility and expense for development and commercial activities for licensed products in the territory and will hold related regulatory approvals and submissions.
- Zymeworks will continue supplying zanidatamab and licensed product to clinical sites under the amended collaboration agreement.
- The filing does not provide transaction consideration, expected proceeds, revenue, profit, cash flow, margins, debt, liquidity, or other quantified financial metrics.
Material changes versus the prior arrangement
- Responsibility for the zanidatamab program will shift from Zymeworks to Jazz, including responsibility for specified ongoing studies and certain South Korean clinical studies.
- Jazz’s nonexclusive license will expand to permit research and development outside the territory for portions of the program conducted outside the territory.
- Jazz will generally own intellectual property arising from the program, subject to specified exceptions for patentable subject matter created by or for Zymeworks before the amended agreement’s effective date.
- Zymeworks will be restricted from using specified clinical data to develop or commercialize other HER2-directed pharmaceutical products in the territory, excluding zanidatamab zovodotin.
- The parties will enter into a transition services agreement to support the transfer of assets and program responsibilities.
Outlook, risks, and unusual items
- Closing and execution of the amended collaboration agreement were expected in May 2023, but the filing does not confirm that closing occurred.
- The transaction is intended to simplify, focus, and potentially expedite zanidatamab’s clinical development and commercialization in partnership with Jazz.
- Acquired assets exclude Zymeworks’ intellectual property and assets related to zanidatamab zovodotin, also known as ZW49.
- The transaction remains subject to the terms and conditions of the transfer agreement. The filing describes customary representations, warranties, covenants, confidentiality obligations, indemnities, and transition arrangements.
- Forward-looking statements regarding closing, timing, anticipated benefits, and post-closing results are subject to risks and uncertainties, and actual outcomes may differ materially.
Investor verification points
- Verify whether the anticipated May 2023 closing and amended collaboration agreement were completed and review the final filed agreements.
- Review the transfer agreement and amended collaboration agreement for consideration, conditions, termination rights, indemnities, and detailed allocation of liabilities.
- Assess the financial impact of Jazz assuming program costs and Zymeworks’ continuing supply obligations.
- Confirm the scope of transferred employees, contractors, contracts, regulatory rights, and clinical studies.
- Evaluate the effect of the intellectual-property ownership provisions and the restrictions on Zymeworks’ use of specified clinical data and development activities.